ZIMBA: Clinical Trial in Paediatric Obesity

PHASE4CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 5, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

March 10, 2024

Conditions
Obesity, ChildhoodInsulin ResistanceZinc DeficiencyInositol
Interventions
DIETARY_SUPPLEMENT

Zinc

In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)

DRUG

Placebos

In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.

DRUG

Myoinositol

In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)

Trial Locations (1)

28100

AOU Maggiore della Carità - Clinica Pediatrica - Ambulatorio di Auxologia ed Endocrinologia Pediatrica, Novara

All Listed Sponsors
lead

Azienda Ospedaliero Universitaria Maggiore della Carita

OTHER

NCT03283813 - ZIMBA: Clinical Trial in Paediatric Obesity | Biotech Hunter | Biotech Hunter